274 related articles for article (PubMed ID: 7537960)
1. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.
Moser TL; Enghild JJ; Pizzo SV; Stack MS
Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):867-73. PubMed ID: 7537960
[TBL] [Abstract][Full Text] [Related]
2. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
[TBL] [Abstract][Full Text] [Related]
3. Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cells.
Schmitt M; Chucholowski N; Busch E; Hellmann D; Wagner B; Goretzki L; Jänicke F; Günzler WA; Graeff H
Semin Thromb Hemost; 1991 Jul; 17(3):291-302. PubMed ID: 1724574
[TBL] [Abstract][Full Text] [Related]
4. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
Hajjar KA; Hamel NM
J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.
Solberg H; Løber D; Eriksen J; Ploug M; Rønne E; Behrendt N; Danø K; Høyer-Hansen G
Eur J Biochem; 1992 Apr; 205(2):451-8. PubMed ID: 1374026
[TBL] [Abstract][Full Text] [Related]
7. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens.
Reuning U; Bang NU
Arterioscler Thromb; 1992 Oct; 12(10):1161-70. PubMed ID: 1327097
[TBL] [Abstract][Full Text] [Related]
9. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system.
Killeen SD; Wang JH; Andrews EJ; Redmond HP
Br J Cancer; 2009 May; 100(10):1589-602. PubMed ID: 19436306
[TBL] [Abstract][Full Text] [Related]
10. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator.
Moser TL; Enghild JJ; Pizzo SV; Stack MS
J Biol Chem; 1993 Sep; 268(25):18917-23. PubMed ID: 8360181
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction.
Li C; Liu JN; Gurewich V
J Biol Chem; 1995 Dec; 270(51):30282-5. PubMed ID: 8530448
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin.
Deng G; Curriden SA; Hu G; Czekay RP; Loskutoff DJ
J Cell Physiol; 2001 Oct; 189(1):23-33. PubMed ID: 11573201
[TBL] [Abstract][Full Text] [Related]
13. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin.
Salonen EM; Vaheri A; Pöllänen J; Stephens R; Andreasen P; Mayer M; Danø K; Gailit J; Ruoslahti E
J Biol Chem; 1989 Apr; 264(11):6339-43. PubMed ID: 2467912
[TBL] [Abstract][Full Text] [Related]
14. Identification of the urokinase receptor as an adhesion receptor for vitronectin.
Wei Y; Waltz DA; Rao N; Drummond RJ; Rosenberg S; Chapman HA
J Biol Chem; 1994 Dec; 269(51):32380-8. PubMed ID: 7528215
[TBL] [Abstract][Full Text] [Related]
15. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.
Seiffert D; Mimuro J; Schleef RR; Loskutoff DJ
Cell Differ Dev; 1990 Dec; 32(3):287-92. PubMed ID: 1711915
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.
Germer M; Kanse SM; Kirkegaard T; Kjøller L; Felding-Habermann B; Goodman S; Preissner KT
Eur J Biochem; 1998 May; 253(3):669-74. PubMed ID: 9654064
[TBL] [Abstract][Full Text] [Related]
17. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy.
Waltz DA; Chapman HA
J Biol Chem; 1994 May; 269(20):14746-50. PubMed ID: 7514182
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
Sitter T; Toet K; Quax P; Kooistra T
Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
[TBL] [Abstract][Full Text] [Related]
19. Urokinase binding to laminin-nidogen. Structural requirements and interactions with heparin.
Stephens RW; Aumailley M; Timpl R; Reisberg T; Tapiovaara H; Myöhänen H; Murphy-Ullrich J; Vaheri A
Eur J Biochem; 1992 Aug; 207(3):937-42. PubMed ID: 1499567
[TBL] [Abstract][Full Text] [Related]
20. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3).
Ugwu F; Van Hoef B; Bini A; Collen D; Lijnen HR
Biochemistry; 1998 May; 37(20):7231-6. PubMed ID: 9585535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
